Placid Jover Sells 14,150 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Key Points

• Insider sale: Placid Jover sold 14,150 shares of Teva at an average price of $31.67 on March 5 for $448,130.50, cutting their stake by 67.63% to 6,774 shares, according to an SEC filing.
• Earnings beat and guidance: Teva reported Q results of $0.96 EPS (vs. $0.65 est.) and $4.71B revenue (+11.4% YoY) and set FY2026 guidance of $2.57–$2.77 EPS, roughly in line with sell‑side expectations of ~2.5 EPS.
• Market and analyst sentiment: Shares traded around $31.44 (up ~1.3%) on above‑average volume, multiple firms raised price targets and ratings (consensus target ~$37.67) with the analyst mix skewing toward Buy.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) insider Placid Jover sold 14,150 shares of the stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $448,130.50. Following the sale, the insider directly owned 6,774 shares of the company's stock, valued at $214,532.58. This represents a 67.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Teva Pharmaceutical Industries Trading Up 1.3%

Shares of NYSE TEVA traded up $0.39 during midday trading on Monday, reaching $31.44. The stock had a trading volume of 11,093,245 shares, compared to its average volume of 9,695,220. The firm has a market cap of $36.15 billion, a price-to-earnings ratio of 26.20, a price-to-earnings-growth ratio of 10.39 and a beta of 0.72. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $37.35. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04. The company's 50 day moving average price is $33.01 and its 200 day moving average price is $26.32.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The company had revenue of $4.71 billion during the quarter, compared to analysts' expectations of $4.36 billion. During the same period in the prior year, the company posted $0.71 earnings per share. Teva Pharmaceutical Industries's revenue for the quarter was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, sell-side analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Hedge funds and other institutional investors have recently modified their holdings of the company. Aster Capital Management DIFC Ltd acquired a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth approximately $25,000. Allworth Financial LP grew its position in Teva Pharmaceutical Industries by 53.8% in the 4th quarter. Allworth Financial LP now owns 941 shares of the company's stock valued at $29,000 after purchasing an additional 329 shares during the period. Grove Bank & Trust increased its stake in Teva Pharmaceutical Industries by 300.0% during the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company's stock valued at $31,000 after purchasing an additional 750 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in Teva Pharmaceutical Industries by 51.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company's stock valued at $32,000 after purchasing an additional 345 shares in the last quarter. Finally, Advisors Asset Management Inc. acquired a new position in Teva Pharmaceutical Industries during the second quarter worth $41,000. Institutional investors own 54.05% of the company's stock.

Analyst Upgrades and Downgrades

TEVA has been the topic of a number of recent analyst reports. Wall Street Zen raised Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research note on Saturday, January 31st. Truist Financial increased their price target on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a "buy" rating in a report on Wednesday, February 18th. Piper Sandler reiterated an "overweight" rating and issued a $41.00 price objective (up from $40.00) on shares of Teva Pharmaceutical Industries in a research note on Wednesday, March 4th. Bank of America increased their target price on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a "buy" rating in a research note on Tuesday, December 9th. Finally, The Goldman Sachs Group lifted their price target on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a "buy" rating in a research note on Monday, February 9th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $37.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.